Cargando…

Somatostatin analogues labeled with copper radioisotopes: current status

Peptide receptor radionuclide therapy (PRRT) is a promising way to treat patients with inoperable tumors or metastatic neuroendocrine tumors. This therapeutic strategy is using radiolabeled peptides, which are capable of selective biding to receptors overexpressed in the cancer cells. One of the gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Marciniak, Aleksandra, Brasuń, Justyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533839/
https://www.ncbi.nlm.nih.gov/pubmed/28804185
http://dx.doi.org/10.1007/s10967-017-5323-x
_version_ 1783253680798040064
author Marciniak, Aleksandra
Brasuń, Justyna
author_facet Marciniak, Aleksandra
Brasuń, Justyna
author_sort Marciniak, Aleksandra
collection PubMed
description Peptide receptor radionuclide therapy (PRRT) is a promising way to treat patients with inoperable tumors or metastatic neuroendocrine tumors. This therapeutic strategy is using radiolabeled peptides, which are capable of selective biding to receptors overexpressed in the cancer cells. One of the group of receptor-avid peptide used in the PRRT are the analogues of somatostatin (SST) connected to the complexes of radionuclides (e.g. (90)Y, (177)Lu or (111)In). Many studies have shown that radiopharmaceuticals based on Cu radioisotopes are promising for the diagnosis and treatment of various cancers. This mini-review focuses on recent developments and summarises the results of multiple studies addressing SST agonists and antagonists radiolabeled to Cu radioisotopes.
format Online
Article
Text
id pubmed-5533839
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-55338392017-08-11 Somatostatin analogues labeled with copper radioisotopes: current status Marciniak, Aleksandra Brasuń, Justyna J Radioanal Nucl Chem Article Peptide receptor radionuclide therapy (PRRT) is a promising way to treat patients with inoperable tumors or metastatic neuroendocrine tumors. This therapeutic strategy is using radiolabeled peptides, which are capable of selective biding to receptors overexpressed in the cancer cells. One of the group of receptor-avid peptide used in the PRRT are the analogues of somatostatin (SST) connected to the complexes of radionuclides (e.g. (90)Y, (177)Lu or (111)In). Many studies have shown that radiopharmaceuticals based on Cu radioisotopes are promising for the diagnosis and treatment of various cancers. This mini-review focuses on recent developments and summarises the results of multiple studies addressing SST agonists and antagonists radiolabeled to Cu radioisotopes. Springer Netherlands 2017-06-13 2017 /pmc/articles/PMC5533839/ /pubmed/28804185 http://dx.doi.org/10.1007/s10967-017-5323-x Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Marciniak, Aleksandra
Brasuń, Justyna
Somatostatin analogues labeled with copper radioisotopes: current status
title Somatostatin analogues labeled with copper radioisotopes: current status
title_full Somatostatin analogues labeled with copper radioisotopes: current status
title_fullStr Somatostatin analogues labeled with copper radioisotopes: current status
title_full_unstemmed Somatostatin analogues labeled with copper radioisotopes: current status
title_short Somatostatin analogues labeled with copper radioisotopes: current status
title_sort somatostatin analogues labeled with copper radioisotopes: current status
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533839/
https://www.ncbi.nlm.nih.gov/pubmed/28804185
http://dx.doi.org/10.1007/s10967-017-5323-x
work_keys_str_mv AT marciniakaleksandra somatostatinanalogueslabeledwithcopperradioisotopescurrentstatus
AT brasunjustyna somatostatinanalogueslabeledwithcopperradioisotopescurrentstatus